Biocentury.com

The French drug maker’s CEO Olivier Brandicourt once more showcased his deal discipline, but he could also do without pesky Americans snapping up his targets. By Paul Whitfield Sanofi SA’ CEO Olivier Brandicourt must be tiring of losing biotech targets...

Johnson & Johnson CEO Alex Gorsky will be sitting pretty as head of an even larger firm once the deal goes through On January 26, Johnson & Johnson, the world’s largest healthcare company, announced it will acquire Swiss pharmaceuticals and...

In the previous press release the companies omitted the cash amount with which R&D NewCo will launch. This has now been rectified and noted as CHF 1 billion. Actelion Shareholders to Receive $280 Per Actelion Share in All-Cash Tender Offer to be...

London/New York: The Johnson & Johnson has approached Actelion Ltd about a potential takeover of the $17 billion Swiss drugmaker as the US health-care giant works to expand its pharmaceutical lineup, people familiar with the matter said. Deliberations...

Johnson & Johnson (No. 8 on the DiversityInc Top 50 Companies list) and Actelion Ltd. announced January 26 that they have entered into a definitive transaction agreement under which Johnson & Johnson will launch an all-cash tender offer in Switzerland...